Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise
Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.
bovnews14d
Gilead Sciences Inc (GILD) Stock Dive: The Hidden Causes Revealed
BofA Securities has recently resumed Gilead Sciences Inc (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had initiated ...
Business Today15d
Solara Active Pharma Sciences Ltd (SOLARA) Share Price
Solara Active Pharma Sciences Ltd share price was down by -1.11% from the previous closing price of ₹682.85. Who are peers of Solara Active Pharma Sciences Ltd? The peers of Solara Active Pharma ...
Yahoo Finance15d
Jim Cramer on Gilead Sciences, Inc. (GILD): ‘I Don’t Think The Business Is Worth As Much As The Stock Is Selling’
We recently compiled a list of the Jim Cramer Talked About These 8 Stocks. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other stocks Jim ...
bovnews16d
Gilead Sciences, Inc. (GILD) Stock Sees Market Value Hit $117.09 billion: What Are the Implications?
BofA Securities has recently resumed Gilead Sciences, Inc. (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...
Pharmaceutical Technology16d
GS-0201 by Gilead Sciences for Solid Tumor: Likelihood of Approval
GS-0201 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...
Pharmaceutical Technology17d
GS-0272 by Gilead Sciences for Rheumatoid Arthritis: Likelihood of Approval
GS-0272 is under clinical development by Gilead Sciences and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 69% phase transition ...
Indiatimes18d
BLACKPINK net worth: Lisa, Rosé, Jennie or Jisoo – find out the richest member of the group in 2024
BLACKPINK will make a full return in 2025 with a world tour. Lisa is the wealthiest member with a net worth of $25 million, thanks to her hit singles and brand endorsements. Rosé, Jennie ...
Stockhouse18d
AI/ML Innovations Closes Acquisition of Quantum Sciences Ltd.
2024 ("Acquisition") and acquired all of the issued and outstanding shares of Quantum Sciences Ltd. ("Quantum"). Quantum specializes in developing innovative digital healthcare solutions powered by ...
Yahoo Finance19d
Gilead Sciences (GILD) Made Big Announcements in Q3
Polaris Global Equity Strategy highlighted stocks like Gilead Sciences, Inc. (NASDAQ:GILD), in the third quarter 2024 investor letter. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical ...